# Amgen

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/amgen
Canonical HTML page: https://getbiobrief.com/entity/amgen

## Timeline

- **2026-07-16**: FDA Approves Lipfendra — The FDA approved Lipfendra (enlicitide), the first once-daily oral PCSK9 inhibitor, for adults with hypercholesterolemia including inherited forms, based on Phase 3 CORALreef trials showing 56-59% LDL-C reduction.

## Recent coverage (5 stories)

### Amgen's Enbrel Copay Assistance Nullified: Insurer Seizes $7,700/Month Coupon
2026-07-27 10:59:55 · Sentiment: Neutral · Impact: 5/10 · Sources: 4

Drugmaker copay assistance programs are meant to lower barriers to high-cost specialty drugs, but accumulator programs circumvent them. For Amgen and other pharma companies, this practice threatens patient adherence and undermines the value of patient support initiatives.
Full story: https://getbiobrief.com/story/copay-accumulator-pharma-strategy

### Merck’s oral PCSK9 inhibitor hits 59% LDL cut, leapfrogging injectable rivals
2026-07-16 22:00:10 · Sentiment: Strongly positive · Impact: 9/10 · Sources: 132

Merck won FDA approval for Lipfendra, a small-molecule oral PCSK9 inhibitor that achieved 56-59% LDL-C reductions in Phase 3. This breakthrough in oral delivery challenges the dominance of injectable biologics from Amgen and Sanofi/Regeneron.
Full story: https://getbiobrief.com/story/merck-lipfendra-fda-approval-oral-pcsk9-59-percent

### Amgen’s $36.8B Pipeline vs NovoCure’s Tumor-Fighting Tech: Which Innovator Wins?
2026-06-28 04:07:18 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Amgen brings a massive $36.8B revenue base and a broad chronic disease pipeline, while NovoCure pushes the frontier with electric‑field cancer therapy. This analysis weighs drug development scale against device‑based oncology innovation for biotech investors.
Full story: https://getbiobrief.com/story/amgen-vs-novocure-biopharma-innovation-2026

### Coherus BioSciences Q4 2025 Preview: Oncology Pivot and Udenyca Onbody Growth
2026-03-08 22:54:39 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Coherus BioSciences is set to report Q4 2025 earnings as it completes its strategic transition into a pure-play oncology firm. Investors are focused on the commercial ramp of Loqtorzi and the market share recovery of the Udenyca franchise following the launch of its Onbody injector.
Full story: https://getbiobrief.com/story/coherus-biosciences-q4-2025-earnings-preview-oncology-strategy

### Statin Dominance Challenged by Growing Patient Advocacy for Treatment Choice
2026-02-22 11:01:18 · Sentiment: Neutral · Impact: 5/10 · Sources: 10

A widespread media narrative is challenging the clinical hegemony of statins, highlighting a perceived lack of transparency regarding side effects and alternative cardiovascular therapies. This shift in public discourse signals a growing demand for patient autonomy that could impact the long-term market share of traditional lipid-lowering blockbusters.
Full story: https://getbiobrief.com/story/statin-controversy-heart-disease-treatment-choice

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.